Comorbidities in patients with Unverricht-Lundborg disease (EPM1).

"CONFLICT OF INTEREST Jussi Sipilä has received honoraria (Merck, Pfizer, Sanofi), a consultancy fees (Rinnekoti Foundation, Medaffcon), travel grants and congress sponsorship (AbbVie, Orion Pharma, Merck Serono, Sanquin, Lundbeck, Novartis) and holds shares (Orion Corporation). Reetta Kälviäinen has received grants from the Academy of Finland and Saastamoinen Foundation, speaker's honoraria from Eisai, Omamedical, Orion, Sandoz, Sanofi, and UCB and honoraria for membership of the advisory boards of Angelini Pharma, Eisai, GW Pharmaceuticals, Marinus Pharmaceuticals, Orion, Takeda and UCB."

"FUNDING INFORMATION This study was supported by grants from the Maire Jokinen Foundation. The sponsor had no role in study design, data collection, data analysis, data interpretation or writing of the article. The authors had full and unimpeded access to all data and the final responsibility for the decision to submit for publication."